Supply Chain | May 14, 2024
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
EBITDA before special items falls 1.3 percent to € 4.41 billion
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
The project funding will be done through a mix of internal accruals and debts.
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
The joint venture will help JV Partners combine their strengths and grow their complementary nutraceuticals portfolios
Sales reflect continued strong growth in oncology and vaccines
Subscribe To Our Newsletter & Stay Updated
